Published in Headache on January 06, 2012
Studies on the pathophysiology and genetic basis of migraine. Curr Genomics (2013) 0.94
mRNA blood expression patterns in new-onset idiopathic pediatric epilepsy. Epilepsia (2012) 0.81
Gene co-expression analysis identifies brain regions and cell types involved in migraine pathophysiology: a GWAS-based study using the Allen Human Brain Atlas. Hum Genet (2016) 0.78
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (2003) 52.74
The International Classification of Headache Disorders: 2nd edition. Cephalalgia (2004) 49.94
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Migraine prevalence, disease burden, and the need for preventive therapy. Neurology (2007) 6.57
Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A (2003) 6.49
Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A (2005) 3.49
Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease. Ann Neurol (2001) 2.44
Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab (2006) 2.20
Cumulative lifetime migraine incidence in women and men. Cephalalgia (2008) 1.73
Patterns of health care utilization for migraine in England and in the United States. Neurology (2003) 1.57
Brain genomic response following hypoxia and re-oxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance. J Biol Chem (2002) 1.52
Menstrual migraine in adolescents. Headache (2009) 1.44
Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. Genomics (2006) 1.39
Genomic responses of the brain to ischemic stroke, intracerebral haemorrhage, kainate seizures, hypoglycemia, and hypoxia. Eur J Neurosci (2002) 1.37
The family impact of migraine: population-based studies in the USA and UK. Cephalalgia (2003) 1.31
Brain genomics of intracerebral hemorrhage. J Cereb Blood Flow Metab (2006) 1.30
Epidemiology and biology of menstrual migraine. Headache (2008) 1.26
Blood expression profiles for tuberous sclerosis complex 2, neurofibromatosis type 1, and Down's syndrome. Ann Neurol (2004) 1.25
Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis--part 2. Headache (2006) 1.14
Blood gene expression profiling of neurologic diseases: a pilot microarray study. Arch Neurol (2005) 1.11
Blood genomic expression profile for neuronal injury. J Cereb Blood Flow Metab (2003) 1.10
Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache (2000) 1.10
Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache (2001) 1.09
Genomic-scale gene expression profiling of normal and malignant immune cells. Curr Opin Immunol (2000) 1.08
Human blood genomics: distinct profiles for gender, age and neurofibromatosis type 1. Brain Res Mol Brain Res (2004) 1.08
Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia (2009) 1.03
Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis--part I. Headache (2006) 1.02
Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine. J Headache Pain (2007) 1.00
Prevention and treatment of menstrual migraine. Drugs (2010) 1.00
Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology (2008) 0.98
Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study. Acta Neurol Scand (2004) 0.95
Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies. Gend Med (2010) 0.93
Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation. Headache (2009) 0.92
Genomic abnormalities in patients with migraine and chronic migraine: preliminary blood gene expression suggests platelet abnormalities. Headache (2004) 0.92
Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache (2007) 0.90
Genomic expression patterns in medication overuse headaches. Cephalalgia (2010) 0.89
Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol (2005) 0.89
Frovatriptan for acute treatment of migraine associated with menstruation: results from an open-label postmarketing surveillance study. J Womens Health (Larchmt) (2009) 0.87
Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurol Sci (2005) 0.86
Assessing quality and normalization of microarrays: case studies using neurological genomic data. Acta Neurol Scand (2008) 0.82
Safety and tolerability of short-term preventive frovatriptan: a combined analysis. Headache (2009) 0.82
Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine. Headache (2007) 0.81
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology (2005) 0.79
Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers. Clin Drug Investig (2009) 0.79
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res (2003) 7.86
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science (2009) 4.16
Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A (2007) 3.84
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet (2002) 2.23
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev (2010) 1.95
Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci U S A (2005) 1.82
Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell (2009) 1.77
Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell (2003) 1.76
Leupeptin inhibits ventilator-induced diaphragm dysfunction in rats. Am J Respir Crit Care Med (2007) 1.74
Towards patient-based cancer therapeutics. Nat Biotechnol (2010) 1.63
Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology (2013) 1.41
Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology (2013) 1.26
PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer. Cancer Res (2002) 1.20
Oncogenic potential of TASK3 (Kcnk9) depends on K+ channel function. Proc Natl Acad Sci U S A (2003) 1.17
Rocuronium exacerbates mechanical ventilation-induced diaphragm dysfunction in rats. Crit Care Med (2006) 1.15
Rotational vertebral artery occlusion in a child with multiple strokes: a case-based update. Childs Nerv Syst (2010) 1.09
Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A (2009) 1.09
Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia (2008) 1.08
Exercise training provides cardioprotection against ischemia-reperfusion induced apoptosis in young and old animals. Exp Gerontol (2005) 1.06
Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther (2010) 1.06
The SRPHK1 outcome measure for cocaine-dependence trials combines self-report, urine benzoylecgonine levels, and the concordance between the two to determine a cocaine-use status for each study day. Drug Alcohol Depend (2007) 1.03
A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. Drug Alcohol Depend (2007) 1.02
Increased antioxidant capacity does not attenuate muscle atrophy caused by unweighting. J Appl Physiol (1985) (2002) 1.01
G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers. Oncogene (2004) 1.00
Identification of alterations in DNA copy number in host stromal cells during tumor progression. Proc Natl Acad Sci U S A (2006) 0.99
A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence. Drug Alcohol Depend (2007) 0.99
Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole. J Child Adolesc Psychopharmacol (2014) 0.99
A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia (2011) 0.98
Wip1-deficient mice are resistant to common cancer genes. Trends Mol Med (2004) 0.96
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model. Int J Cancer (2008) 0.95
Impaired auditory information processing during acute migraine: a magnetoencephalography study. Int J Neurosci (2011) 0.95
Effectiveness of topiramate in the prevention of childhood headaches. Headache (2002) 0.93
Methylphenidate and cocaine: a placebo-controlled drug interaction study. Pharmacol Biochem Behav (2006) 0.91
Modeling the developmental patterns of auditory evoked magnetic fields in children. PLoS One (2009) 0.87
Aberrant neuromagnetic activation in the motor cortex in children with acute migraine: a magnetoencephalography study. PLoS One (2012) 0.86
Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation. J Psychiatr Res (2011) 0.85
Illicit drug use correlates with negative urine drug test results for prescribed hydrocodone, oxycodone, and morphine. Pain Physician (2012) 0.83
Paradoxically high adiponectin and the healthy obese phenotype in obese black and white 16-year-old girls. Transl Res (2010) 0.82
Exercise does not increase cyclooxygenase-2 myocardial levels in young or senescent hearts. J Physiol Sci (2010) 0.82
Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1). Oncotarget (2011) 0.82
Neuromagnetic evidence of impaired cortical auditory processing in pediatric intractable epilepsy. Epilepsy Res (2010) 0.81
Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients. Am J Hematol (2006) 0.80
Cerebral glucose hypometabolism is associated with mitochondrial dysfunction in patients with intractable epilepsy and cortical dysplasia. Epilepsia (2014) 0.79
Early clinical indicators of developmental outcome in abusive head trauma. Childs Nerv Syst (2012) 0.79
New views into the prostate cancer genome. Cancer Cell (2010) 0.79
Neuromagnetic measures of word processing in bilinguals and monolinguals. Clin Neurophysiol (2011) 0.78
Tension-type headache in the young. Curr Pain Headache Rep (2006) 0.77
High-content analysis of cancer genome DNA alterations. Curr Opin Genet Dev (2008) 0.77
Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response. Physiol Behav (2012) 0.76
OnabotulinumtoxinA in pediatric chronic daily headache. Curr Neurol Neurosci Rep (2012) 0.76
Inducing stable reversion to achieve cancer control. Nat Rev Cancer (2016) 0.76
Response to the Letter by Masuo R., et al. J Clin Endocrinol Metab (2015) 0.75
The future of research universities. Is the model of research-intensive universities still valid at the beginning of the twenty-first century? EMBO Rep (2007) 0.75
Reference intervals: a novel approach to detect drug abuse in a pain patient population. J Opioid Manag (2010) 0.75
Pediatric and adolescent migraine. Headache (2012) 0.75
Magnetoencephalography reveals altered auditory information processing in youth with obsessive-compulsive disorder. Psychiatry Res (2013) 0.75